Clostridium botulinum
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Clostridium botulinum
- DrugBank Accession Number
- DB14223
- Background
Not Available
- Type
- Biotech
- Groups
- Experimental
- Synonyms
- Bacillus botulinus whole
- Bacillus putrificus whole
- Botulobacillus botulinus whole
- Clostridium botulinum whole
- Clostridium putrificum whole
- Ermengemillus botulinus whole
- Pacinia putrifica whole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Ankle spasticity following a stroke or traumatic brain injury •••••••••••• ••••• •••••••••• ••••••• ••• •••••••• Symptomatic treatment of Axillary hyperhidrosis •••••••••••• ••••• •••••••••• ••••••• ••• •••••••• Symptomatic treatment of Blepharospasm •••••••••••• ••••• •••••••••• ••••••• ••• •••••••• Symptomatic treatment of Cervical dystonia •••••••••••• ••••• •••••••••• ••••••• ••• •••••••• Symptomatic treatment of Equinus foot deformity in children with cerebral palsy •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Protoxin Gel 10 g/10mL Topical Protox Inc. 2016-11-10 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Protoxin Clostridium botulinum (10 g/10mL) Gel Topical Protox Inc. 2016-11-10 Not applicable US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0296055VE0
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- 1811178
- Wikipedia
- Clostridium_botulinum
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Terminated Treatment Scarring 1 3 Active Not Recruiting Treatment Glabellar Frown Lines (GL) 1 3 Completed Treatment Electromyography / ElectroPhys: Myopathy / EMG Syndrome / EMG: Myopathy / Pelvic Floor Disorders / Pelvic Pain / Pelvic Pain Syndrome 1 3 Completed Treatment Glabellar Frown Lines (GL) 2 3 Completed Treatment Moderate to Severe Glabellar Frown Lines 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intramuscular Injection, powder, for solution Intramuscular 125 SU Injection, powder, for solution Parenteral 100 Einheiten Injection, powder, for solution Parenteral 4 Einheiten/0.1ml Injection, powder, for solution Parenteral 50 Einheiten Injection, powder, for solution Parenteral 100 U Injection, powder, for solution Parenteral Injection, powder, for solution Parenteral 200 U Injection, powder, for solution Parenteral 50 U Injection, powder, for solution Parenteral 500 Einheiten Injection, powder, for solution Intramuscular; Subcutaneous 300 u/vial Injection, powder, for solution Intramuscular; Subcutaneous 500 U/vial Injection, powder, lyophilized, for solution Intramuscular 100 Units Gel Topical 10 g/10mL Injection, powder, for solution Parenteral 0.1 ml Injection, powder, for solution Parenteral 200 Einheiten - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at July 04, 2018 22:46 / Updated at February 13, 2021 10:53